Kyowa Kirin gets extended EC approval for CRYSVITA in X-linked hypophosphataemia
Kyowa Kirin has secured extended approval for CRYSVITA (burosumab) from the European Commission (EC) in X-linked hypophosphataemia (XLH), to cover the treatment of older adolescents ... Read More
Ultragenyx Pharmaceutical, Kyowa Kirin bag Crysvita FDA approval for TIO
Crysvita FDA approval for TIO : Ultragenyx Pharmaceutical and Kyowa Kirin have secured approval for their recombinant fully human monoclonal IgG1 antibody Crysvita (burosumab) from ... Read More